The FLOW trial
The kidney outcome in FLOW
Well can mean something preserved. This trial gives that hope a specific population and a demanding outcome.
The FLOW population
In existing illness, preservation seems a more worthwhile ambition to me than transformation: something valuable continuing. In FLOW, semaglutide reduced major kidney-disease events versus placebo in people with type 2 diabetes and chronic kidney disease. The trial enrolled 3,533 people with both conditions.
That both matters. It is easy to imagine a general kidney-health story after seeing a favourable result. The actual trial supplies a much more particular setting, and that particularity is part of what makes the result useful. Inflating the finding into a general wellness claim would cost the specificity that persuades me.
The reported hazard ratio for the primary kidney composite was 0.76, with a 95% confidence interval of 0.66-0.88: a 24% lower risk versus placebo. The result's importance, to my mind, lies in those consequential outcomes among people already living with illness.
The composite outcome
FLOW's primary outcome combined kidney failure, a decline of at least 50% in eGFR, or death from kidney or cardiovascular causes. A composite gathers several outcomes into the trial's main comparison. Here, it includes death as well as kidney failure and the eGFR decline.
Describing the whole finding as a simple improvement in a kidney number seems too small an account to me. Its subjects are more consequential, and more varied. The reported comparison concerns their combination; it does not supply a separate 24% reduction for every component.
This is where well becomes a demanding word for me. An easier day, fewer cardiovascular events and a kidney composite can all matter, yet each asks for its own account. The untidy collection seems a more honest account than a single flattering verdict. The heart essay adds another event record, while the home page returns to the different ambitions around growing and living well.